drugset / Trial / NCT06773455

Tralokinumab for Dupilumab Failures

NCT06773455 ↗

NaSingle-groupOpen-labelTreatment

Summary

24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.

Timeline

Start
2023-09-11
Primary completion
2026-01-13
Completion
2026-01-13

Outcome

Outcome not reported

Stopped: “Principal Investigator retired”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tralokinumab Monoclonal antibody 300 mg —

Indications